<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>2171</id>
    <completedYear/>
    <publishedYear>2005</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>748</pageFirst>
    <pageLast>753</pageLast>
    <pageNumber/>
    <edition/>
    <issue>4</issue>
    <volume>25</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating</title>
    <abstract language="eng">Objective&#13;
The risk of in-stent restenosis can be considerably reduced by stents eluting cytostatic compounds. We created a novel drug-eluting stent system that includes several new features in the rapidly evolving field of stent-based drug delivery.&#13;
&#13;
Methods and Results&#13;
The aim of the present study was the preclinical evaluation of a stent-coating system permitting individual, on-site coating of stents with a unique microporous surface allowing for individualizable, dose-adjustable, and multiple coatings with identical or various compounds, designated ISAR (individualizable drug-eluting stent system to abrogate restenosis). Stents were coated with 0.75% rapamycin solution, and high-performance liquid chromatography (HPLC)-based determination of drug release profile indicated drug release for &gt;21 days. Rapamycin-eluting microporous (REMP) stents implanted in porcine coronary arteries were safe. To determine the efficacy of REMP stents, this novel drug-eluting stent platform was compared with the standard sirolimus-eluting stent. At 30 days, in-stent neointima formation in porcine coronary arteries was similar in both groups, yielding a significant decrease of neointimal area and injury-dependent neointimal thickness compared with bare-metal stents.&#13;
&#13;
Conclusion&#13;
The ISAR drug-eluting stent platform as a novel concept for stent coating allows for a safe, effective, on-site stent coating process, thus justifying further clinical evaluation to decrease in-stent restenosis in humans.&#13;
In-stent neointima formation can be successfully attenuated by drug-eluting stents. We introduce a novel conceptual approach for stent-coating that allows for dose-adjustable, on-site stent coating process if desired with multiple compounds. Microporous stents coated with rapamycin proved safe and effective for the limitation of neointima formation in a porcine coronary stent model.</abstract>
    <parentTitle language="eng">Arteriosclerosis, Thrombosis, and Vascular Biology</parentTitle>
    <identifier type="doi">10.1161/01.ATV.0000157579.52566.ee</identifier>
    <identifier type="issn">1524-4636</identifier>
    <enrichment key="BegutachtungStatus">peer-reviewed</enrichment>
    <author>Rainer Wessely</author>
    <author>Jörg Hausleiter</author>
    <author>Cornelia Michaelis</author>
    <author>Birgit Jaschke</author>
    <author>Michael Vogeser</author>
    <author>Stefan Milz</author>
    <author>Boris Behnisch</author>
    <author>Thomas Schratzenstaller</author>
    <author>Magdalena Renke-Gluszko</author>
    <author>Michael Stöver</author>
    <author>Erich Wintermantel</author>
    <author>Adnan Kastrati</author>
    <author>Albert Schömig</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>drug-eluting stent</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>stent platform</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>sirolimus</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>rapamycin</value>
    </subject>
    <collection role="ddc" number="610">Medizin und Gesundheit</collection>
    <collection role="institutes" number="FAKMB">Fakultät Maschinenbau</collection>
    <collection role="institutes" number="RCBE">Regensburg Center of Biomedical Engineering - RCBE</collection>
    <collection role="othpublikationsherkunft" number="">Externe Publikationen</collection>
    <collection role="persons" number="schratzenstallermd">Schratzenstaller, Thomas (Prof. Dr.) -Labor Medizinprodukte</collection>
    <collection role="othforschungsschwerpunkt" number="16314">Lebenswissenschaften und Ethik</collection>
    <collection role="institutes" number="">Labor Medizinprodukte</collection>
  </doc>
</export-example>
